Pfizer v. Macleods Pharmaceuticals: Xeljanz Tofacitinib Patent Action Dismissed Without Prejudice
Pfizer and its co-plaintiffs filed suit in the Delaware District Court asserting patent USRE041783E — covering tofacitinib, the active ingredient in Xeljanz — against Macleods Pharmaceuticals’ generic tablet product. The case closed just 55 days after filing when Pfizer voluntarily dismissed all claims without prejudice before Macleods had served any responsive pleading.
Pfizer’s Pre-Answer Dismissal Keeps Xeljanz Patent Claims Alive
On 21 May 2025, Pfizer Inc. together with C.P. Pharmaceuticals International C.V., PF PRISM C.V., PBG Puerto Rico LLC, and PF PRISM IMB B.V. filed a patent infringement action in the Delaware District Court against Macleods Pharmaceuticals Ltd. The complaint asserted reissue patent USRE041783E — a reissued patent corresponding to U.S. application 12/577790 and covering the tofacitinib compound underlying Pfizer’s branded Xeljanz 5 mg and 10 mg tablets — in response to Macleods’ apparent effort to market a generic tofacitinib tablet product.
On 15 July 2025, just 55 days after filing, Pfizer invoked Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure to file a unilateral notice of voluntary dismissal without prejudice. Because Macleods had not yet served an answer or a motion for summary judgment at the time the notice was filed, Pfizer was entitled as of right to dismiss — no court order was required and no merits ruling was issued. Dismissal without prejudice means Pfizer’s patent claims against Macleods on USRE041783E are formally terminated for now but remain available for future litigation.
A 55-day lifecycle with no responsive pleading suggests the parties may have reached a confidential resolution — such as a licensing agreement or negotiated market-entry date — though the public record is entirely silent on any settlement terms. It is also possible Pfizer identified a procedural or strategic reason to refile in a different form. What is clear is that USRE041783E remains in force and Macleods’ generic tofacitinib product has not received any judicial clearance to launch free of infringement risk.
Filing to Dismissed without Prejudice in 55 days
55 days — closed before any responsive pleading was served, well below the ANDA litigation median
Voluntarily dismissed without prejudice: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): a right, not a concession
Under Rule 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order at any time before the defendant serves an answer or a motion for summary judgment. Pfizer exercised this right as of right — the court issued no order and made no merits ruling. The dismissal is purely procedural and carries no implication that the patent is invalid or unenforceable.
No merits adjudicationWithout prejudice: the distinction that matters most
A dismissal without prejudice leaves Pfizer free to refile the same claims against Macleods on USRE041783E at a later date, subject to applicable statutes of limitation. A dismissal with prejudice would have permanently barred those claims. The public record here confirms the dismissal is without prejudice, preserving Pfizer’s full enforcement rights. Whether the parties reached any private arrangement is not disclosed.
Pfizer retains right to refileNo judicial clearance for Macleods’ generic tofacitinib
Macleods obtained no declaratory judgment, no invalidity ruling, and no non-infringement finding. The dismissal without prejudice means the infringement cloud over its generic tofacitinib tablets remains. Macleods faces continued exposure to a future Pfizer suit on USRE041783E if it attempts a commercial launch, and any launch before resolution would carry significant at-risk exposure.
Infringement risk unresolvedUSRE041783E remains an active enforcement tool for Pfizer
The swift voluntary dismissal is consistent with a confidential licensing arrangement or a negotiated agreed market-entry date — a common outcome in ANDA-adjacent disputes. For other generic entrants watching this case, the dismissal provides no precedent on validity or claim scope. Pfizer’s Xeljanz franchise retains its patent protection, and USRE041783E continues to pose a litigation risk for any generic tofacitinib product lacking a licence.
Patent enforcement preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Pfizer, Inc. | Company | Global pharmaceutical company — holder of USRE041783E covering tofacitinib (Xeljanz)Search in Eureka ↗ |
| Defendant | Macleods Pharmaceuticals | Individual | Indian generic pharmaceutical manufacturer seeking U.S. market entry with generic tofacitinib tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Pfizer, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Pfizer, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice explicitly invokes Rule 41(a)(1)(A)(i) and confirms that Macleods had not served an answer or summary judgment motion at the time of filing — a procedural threshold that entitled Pfizer to dismiss as of right without court approval. The phrase ‘without prejudice’ is operative: it forecloses any argument that Pfizer has waived or abandoned its claims under USRE041783E. No merits determination was made, and the patent’s validity and enforceability remain entirely intact.
USRE041783E — tofacitinib reissue patent covering Xeljanz JAK inhibitor tablets
USRE041783E is a reissue patent corresponding to U.S. application 12/577790. Reissue patents are granted by the USPTO when a patentee seeks to correct errors in an already-issued patent — whether to broaden or narrow claims — within the applicable statutory period. The underlying technology covers tofacitinib, a Janus kinase (JAK) inhibitor used orally to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, marketed by Pfizer as Xeljanz at 5 mg and 10 mg doses. The reissue designation means the claim scope may differ from the original granted patent, making prosecution history review essential for any infringement or validity analysis.
Tofacitinib is a blockbuster asset in Pfizer’s immunology portfolio, generating multi-billion dollar revenues globally. The JAK inhibitor class has attracted intense generic competition as branded exclusivities approach expiration, making reissue patent coverage a critical secondary enforcement layer. USRE041783E represents Pfizer’s attempt to preserve or refine claim protection over this molecule, and its continued validity — untouched by this litigation — means competing pharmaceutical companies and generic manufacturers face meaningful litigation exposure when attempting to enter the tofacitinib market without a licence.
Should you run an FTO analysis against USRE041783E before entering the tofacitinib market?
Any pharmaceutical company — generic manufacturer, biosimilar developer, or specialty pharma — with a product containing tofacitinib or a structurally related JAK inhibitor should treat USRE041783E as an active risk. This case confirms Pfizer is willing to enforce the patent in Delaware, and the dismissal without prejudice preserves that enforcement posture fully. Product teams preparing ANDA filings or NDA submissions for tofacitinib tablet formulations should commission FTO analysis that covers both the reissue patent claims and the original prosecution history before any regulatory or commercial commitment.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of USRE041783E — including broadened or narrowed reissue claims — against your specific compound, formulation, or method of manufacture. Eureka surfaces related prosecution history, identifies claim differentiation pathways, and flags co-pending family members that could present additional risk. For JAK inhibitor product teams operating under competitive generic timelines, early and precise FTO analysis is essential before any at-risk launch decision.
Run a freedom-to-operate analysis on USRE041783E to assess your product’s exposure
Run FTO in Eureka →Similar JAK inhibitor and ANDA pharma patent cases in Delaware federal court
Explore related tofacitinib and JAK inhibitor patent infringement actions filed in the Delaware District Court, including other Pfizer Xeljanz enforcement suits and ANDA disputes involving reissue patents.
What this case signals for the JAK inhibitor and branded pharmaceutical IP landscape
A pre-answer voluntary dismissal in an ANDA-style dispute rarely signals weakness — it typically signals leverage, deal-making, or strategic repositioning.
Pre-answer dismissals in pharma patent suits are often deal signals
When a plaintiff of Pfizer’s scale files and then voluntarily dismisses in under 60 days — before any responsive pleading — the most commercially likely explanation is a confidential resolution. IP teams monitoring Xeljanz generic competition should treat this case as a potential indicator of a negotiated entry timeline or licensing arrangement with Macleods rather than patent abandonment.
USRE041783E retains full enforceability against all other generic filers
No court has ruled on the validity, scope, or infringement of USRE041783E. Any other generic pharmaceutical company with a pending ANDA or NDA for tofacitinib tablets cannot rely on this case as clearing the path. Pfizer’s dismissal without prejudice explicitly preserves its ability to assert the same patent against Macleods or any other party.
Pfizer v Macleods — key questions answered
Dismissal without prejudice under Rule 41(a)(1)(A)(i) means Pfizer voluntarily ended this specific action but retains the right to refile the same claims against Macleods under USRE041783E. No merits ruling was issued. The patent remains valid and enforceable, and Macleods received no judicial clearance to launch its generic tofacitinib tablets free of infringement risk.
USRE041783E is a U.S. reissue patent corresponding to application 12/577790, covering tofacitinib — the JAK inhibitor active ingredient in Pfizer’s Xeljanz 5 mg and 10 mg tablets. Reissue patents arise when a patentee corrects the original patent post-grant, potentially broadening or narrowing claim scope. Its coverage of tofacitinib makes it a key enforcement asset against any generic manufacturer seeking ANDA approval for tofacitinib tablets.
The public record does not disclose Pfizer’s reason for dismissal. The timing — 55 days post-filing, before Macleods filed any responsive pleading — is consistent with a confidential licensing or market-entry agreement, a common outcome in pharmaceutical patent disputes. It may also reflect a strategic decision to refile on different grounds. No merits finding was made and Pfizer’s enforcement rights are fully preserved.
The dismissal provides no legal clearance for Macleods to launch. Because the case was dismissed without prejudice and no invalidity or non-infringement ruling was issued, USRE041783E remains a live infringement risk against Macleods’ generic tofacitinib product. An at-risk commercial launch without a licence or court clearance would expose Macleods to a new infringement action by Pfizer.
Rule 41(a)(1)(A)(i) allows a plaintiff to dismiss an action as of right — without court approval — before the defendant has served an answer or a motion for summary judgment. In pharmaceutical patent litigation, this rule is frequently used when parties reach a confidential resolution early in the case. It is a zero-cost, no-admission exit mechanism that preserves the plaintiff’s ability to refile, making it a strategically valuable tool for patent-holders managing a portfolio of ANDA disputes.
PatSnap Eureka searches patents and litigation data to answer instantly.